Gene therapy is moving beyond laboratory proof-of-concept and into a more commercially accountable phase. Approved treatments are producing revenue, reimbursement pathways are becoming clearer, and manufacturing and regulatory execution increasingly determine which companies can translate promising biology into durable businesses. The opportunity remains substantial because many target diseases have high unmet need and gene-based interventions can potentially deliver long-lasting or even curative benefits. However, the same characteristics that create upside also make the category volatile: clinical outcomes, safety findings, payer decisions, and launch execution can rapidly change an investment case.
Investors should distinguish among commercial gene-therapy leaders, platform companies with several shots on goal, and enabling or adjacent rare-disease businesses that can finance pipeline development. The key segments include in vivo AAV gene replacement, ex vivo gene editing and gene addition, and rare-disease franchises with established commercial infrastructure. A notable sign of progress is the continued scaling of Vertex Pharmaceuticals and CRISPR Therapeutics' CASGEVY, which management said generated $76 million in second-quarter 2026 revenue and received FDA approval in younger pediatric patients.
This article presents seven names in countdown order, beginning with rank #7 and ending with the highest-ranked exposure at #1. The ordering first reflects depth of exposure to gene therapy and related genetic medicines, then considers commercial traction, profitability, growth, valuation, and execution evidence. That approach places some financially stronger diversified companies alongside more concentrated clinical-stage opportunities, giving investors a way to compare validated revenue with higher-risk pipeline optionality.
The screen starts with US-listed healthcare companies and a market-cap threshold above $500 million, then applies a thematic filter for direct gene therapy, gene editing, or closely connected genetic-medicine exposure. Within that universe, companies are ranked primarily by the depth of their exposure and secondarily by business fundamentals, including revenue, margins, growth, earnings history, valuation, and analyst consensus. This is a countdown: the best-ranked name is reserved for #1 at the end. The data line for each company uses evergreen metrics rather than a daily share-price snapshot.
What they do. The company develops and commercializes therapies for rare and ultra-rare genetic diseases, including Crysvita, Mepsevii, Dojolvi, and Evkeeza. Its commercial products provide a revenue base, while its development portfolio includes multiple AAV programs and other genetic medicines, giving Ultragenyx a diversified rare-disease position rather than a single-asset profile.
Why it fits. Ultragenyx has direct exposure to in vivo gene therapy through UX111, an AAV9 candidate for Sanfilippo syndrome type A; DTX401, an AAV8 candidate for glycogen storage disease type Ia; DTX301 for ornithine transcarbamylase deficiency; and Phase 2 UX701 for Wilson liver disease. That breadth makes the company relevant to the theme, although its broader commercial portfolio means gene therapy is one part of the investment story.
Numbers that matter. Revenue was $717 million and grew 28.1% year over year, a strong top-line result for a company still funding several clinical programs. The profitability picture is much weaker: gross margin was -20.8%, operating margin was -35.05%, and net margin was -81.73%, with EBITDA of -$465 million. TTM EPS was -$5.83, although the next-year EPS estimate is $0.6767; the available valuation data does not provide a usable P/E figure.
Recent momentum. Ultragenyx beat the latest reported quarterly EPS estimate, posting -$0.90 versus -$1.27 for a 29.1% positive surprise on August 4, 2026. Its overall earnings beat rate is 3 of 7 quarters, so execution has been uneven. Analyst sentiment is nevertheless constructive, with six Buy ratings and one Hold and an average target of $28.05, creating a more favorable forward view than the current loss profile alone would suggest.
What they do. bluebird bio developed and commercialized gene therapies for severe genetic diseases, including ZYNTEGLO for transfusion-dependent beta thalassemia, LYFGENIA for sickle cell disease, and SKYSONA for cerebral adrenoleukodystrophy. Its business model centered on potentially curative, one-time treatments, but the supplied corporate record states that the company was taken private as of May 29, 2025, making current public-market investability an important caveat.
Why it fits. This is one of the most direct gene-therapy businesses in the group, with approved products spanning blood disorders and a devastating neurological disease. The commercial history also illustrates the central theme risk: an approved therapy can demonstrate real clinical value while still facing difficult reimbursement, manufacturing, treatment-center, and launch economics.
Numbers that matter. Revenue was $103.946 million and grew 108.4% year over year, but the company remained deeply unprofitable. Gross margin was 27.1%, operating margin was -55.56%, net margin was -192.39%, and EBITDA was -$149.196 million. TTM EPS was -$20.59, with a next-year EPS estimate of -$5, while the available data does not provide a meaningful P/E valuation.
Recent momentum. The latest reported quarter in the supplied earnings history showed EPS of -$2.6632 versus an estimate of -$4.635, a 42.5% positive surprise. Bluebird beat estimates in 6 of 8 listed quarters, although those beats occurred while losses remained substantial. The analyst breakdown was one Buy and three Holds, with an average target of $8, but the private-company status and stale supplied market data limit how much weight investors should place on that consensus.
What they do. Sarepta is a commercial-stage genetic-medicine company focused on rare disease, with RNA-targeted medicines, RNA interference programs, and gene therapy. Its portfolio includes three Duchenne exon-skipping products and ELEVIDYS, an AAV-based gene therapy, while additional programs address limb-girdle muscular dystrophy and other genetic disorders.
Why it fits. Sarepta offers direct commercial gene-therapy exposure through ELEVIDYS while retaining a broader genetic-medicine platform. That combination gives investors exposure to the transition from approved therapy to commercial execution, but also introduces product-specific safety, eligibility, and payer-access risks that can produce sharp changes in results.
Numbers that matter. Revenue was $1.974 billion, although it declined 34.3% year over year. Gross margin was 19.1%, operating margin was 13.03%, and net margin was -6.93%, while EBITDA was negative $17.533 million. TTM EPS was -$1.57, but the next-year EPS estimate is $2.6322; the forward P/E of 20.3252 reflects a market expectation of improving profitability rather than current earnings strength.
Recent momentum. Sarepta reported EPS of $0.42 versus an estimate of $0.34 in the latest listed quarter, a 23.5% positive surprise, after EPS of $3.16 versus $1.05 in the prior quarter, a 201.0% surprise. The earnings beat rate is 4 of 7 quarters, with significant volatility including a 241.0% miss in March 2026. Analysts remain constructive with eight Buys and four Holds and an average target of $21.86.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
What they do. Novartis is a large international pharmaceutical company with a broad portfolio across cardiovascular, immunology, neuroscience, oncology, and hematology. Its products include Zolgensma for the genetic root cause of spinal muscular atrophy, alongside established medicines such as Entresto, Cosentyx, Kisqali, Pluvicto, and Leqvio, giving it substantial commercial infrastructure and funding capacity.
Why it fits. Zolgensma gives Novartis direct exposure to commercial gene therapy, while the company's scale provides a lower-risk way to participate in genetic medicine than a single-asset biotech. Its ranking is limited by the fact that gene therapy is one product within a diversified pharmaceutical portfolio, rather than the company's central operating focus.
Numbers that matter. Novartis generated $56.693 billion in revenue and $23.098 billion in EBITDA. Gross margin was 75.0%, operating margin was 34.62%, and net margin was 22.5%, with ROE of 30.35% and ROA of 10.25%. Revenue growth was modest at 0.8% year over year and earnings growth was -17%, but the valuation profile was more established than the clinical-stage names, with a trailing P/E of 21.1719 and forward P/E of 14.4718.
Recent momentum. The latest listed quarter produced EPS of $2.41 versus $2.20 expected, a 9.5% positive surprise, and Novartis has beaten estimates in 5 of 7 listed quarters. The analyst group is more measured than for the focused biotech names, with two Buys and nine Holds and an average target of $156.56. That balance reflects strong profitability alongside slower recent growth and more limited gene-therapy exposure.
What they do. Vertex develops and commercializes transformative medicines for serious diseases, with a powerful established franchise in cystic fibrosis and newer products in sickle cell disease, beta thalassemia, and acute pain. Its commercial base includes multiple CF medicines, while CASGEVY expands the company into ex vivo gene-edited cell therapy through its strategic relationship with CRISPR Therapeutics.
Why it fits. CASGEVY gives Vertex exposure to ex vivo gene editing for sickle cell disease and transfusion-dependent beta thalassemia, precisely matching one of the theme's most important commercial sub-segments. Management said CASGEVY generated $76 million in second-quarter 2026 revenue and received FDA approval in younger pediatric patients, evidence that gene-based treatment is becoming part of a scaled commercial business.
Numbers that matter. Vertex reported $12.587 billion in revenue, up 12.5% year over year, and $5.100 billion in EBITDA. Gross margin was 55.0%, operating margin was 38.06%, and net margin was 35.0%, supported by ROE of 23.54% and ROA of 11.93%. TTM EPS was $17.18, the next-year estimate was $20.133, and the trailing and forward P/E ratios were 29.5891 and 23.753, respectively.
Recent momentum. Vertex posted EPS of $4.20 versus $4.15 expected in the latest listed quarter, a 1.2% positive surprise, and beat by 3.8% in the prior quarter. Its earnings beat rate is 4 of 7 quarters. Analysts list four Buys, fourteen Holds, and one Sell, with an average target of $569.19, suggesting confidence in the business but also a relatively balanced view after the company's strong commercial performance.
Pick #2Premium members only
Premium members see this pick's full breakdown — investment thesis, key financial metrics, recent earnings execution, and analyst consensus.
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
This monthly screen begins with US-listed healthcare companies above $500 million in market capitalization and identifies businesses with direct gene-therapy, gene-editing, or closely related genetic-medicine exposure. The ranking gives priority to thematic depth: commercial gene-therapy products and broad, relevant pipelines generally rank ahead of diversified companies with only one genetic-medicine asset. Business fundamentals then serve as the tie-breaker, including revenue scale, growth, profitability, valuation, earnings surprises, and analyst consensus. Composite quality grades are included as a standardized reference, not as a substitute for clinical diligence. The list is refreshed monthly as financial data, earnings history, and company developments change.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
